Active Not RecruitingNCT06116890
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration
PHASE2 · 180 planned enrolment
- Countries listed
- 4
- Registry update
- October 30, 2025
immortal.lifeTrial registrations containing the exact intervention label KHK4951.
No aliases or equivalent products have been inferred.
This is a registry availability fact, not a safety result, comparison, or conclusion.
Understand the safety boundary →PHASE2 · 180 planned enrolment
PHASE1 · 116 planned enrolment